In addition to the concerns about sex-specific results from OXT treatment [193], careful selection of the conditions in which oxytocin treatment should be beneficial for obesity and its comorbidities, and their relevance for human pathology needs to be determined [135]. This evidence concerns the gene OXT and obesity due to melanocortin 4 receptor deficiency.